Cite
HARVARD Citation
Österborg, A. et al. (n.d.). Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 57 (9), pp. 2037-2046. [Online].